Begoña Díaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Begoña Díaz has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Alfred A. Chan
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California. 1
114 shared publications - Daniel Srole
UCLA Center for Iron Disorders, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California. 7
114 shared publications - David B. Shackelford
Pulmonary and Critical Care Medicine, David Geffen School of Medicine (DGSOM), University of California Los Angeles (UCLA), Los Angeles, USA
114 shared publications - Delphine J. Lee
Lundquist Institute For Medical Innovation, Harbor-UCLA Medical Center, Torrance, California, USA; David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, California, USA; Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California, USA
114 shared publications - Elizabeta Nemeth
Center for Iron Disorders, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
114 shared publications - Feng Wang
From the Department of Neurology (S.E.R., A.R.F., J.D., C.W.), Washington University in St. Louis, MO; John Walton Muscular Dystrophy Research Centre (S.L., F.W., M.S., J.D.-M.), Newcastle University and Newcastle Hospitals NHS Foundation Trusts, United Kingdom; and Division of Biology and Biological Engineering (T.-F.C.), California Institute of Technology, Pasadena
114 shared publications
Latest Publications
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Effect of lipid peroxidation on the abundance of TIM17A in lung carcinoma cells.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Effect of lipid peroxidation on the abundance of TIM17A in lung carcinoma cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT alters iron homeostasis in (KL/K)MUT lung carcinoma cells.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT alters iron homeostasis in (KL/K)MUT lung carcinoma cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT prevents cell cycle progression and causes death in lung carcinoma cells.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT prevents cell cycle progression and causes death in lung carcinoma cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
NMTi treatment induces features of parthanatos in vitro and in vivo.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
NMTi treatment induces features of parthanatos in vitro and in vivo.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Genetic targeting of NMT1 decreases the viability of (KL/K)MUT lung carcinoma.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Genetic targeting of NMT1 decreases the viability of (KL/K)MUT lung carcinoma.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT increases mitochondrial ferrous iron content in (KL/K)MUT but not (KL/K)WT lung carcinoma cells.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Inhibition of NMT increases mitochondrial ferrous iron content in (KL/K)MUT but not (KL/K)WT lung carcinoma cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Mitochondria is a key target of NMT inhibitors.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Mitochondria is a key target of NMT inhibitors.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
MS data of H1792 cells treated with NMTi
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
MS data of H1792 cells treated with NMTi
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Treatment with necroptosis and pyroptosis inhibitors fail to prevent cell death induced by of NMTi treatment in lung carcinoma cells.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
Treatment with necroptosis and pyroptosis inhibitors fail to prevent cell death induced by of NMTi treatment in lung carcinoma cells.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
The PARP inhibitor olaparib rescues death induced by NMTi treatment.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma
The PARP inhibitor olaparib rescues death induced by NMTi treatment.